Benefits
Mild to moderate depression treatment
The most comprehensive meta-analysis of St. John's Wort (29 RCTs, 5,489 patients) confirms it is significantly more effective than placebo and similarly effective to standard antidepressants (SSRIs, TCAs) for mild-to-moderate depression — with significantly fewer side effects and better tolerability. Particularly well-established in European clinical practice where it is licensed as a pharmaceutical in several countries. Evidence is strongest for mild-to-moderate presentations: the large US trial (Davidson 2002, JAMA, n=340) found no benefit over placebo in more severe major depression, so it should not be relied on for severe depression.
Anxiety and stress reduction
Beyond depression, SJW is sometimes used to help ease everyday anxiety, irritability, and psychological stress. This is a separate and more limited area of evidence than the depression research and is not established by the meta-analyses cited here. The mechanism involves GABAergic modulation and serotonin reuptake inhibition, producing calming effects that complement the antidepressant activity.
Seasonal affective disorder (SAD)
St. John's Wort has been studied for seasonal affective disorder (winter low mood), with a trial reporting effects comparable to light therapy. This is a separate, limited area of evidence and is not established by the meta-analyses cited here; anyone with seasonal depression should work with a clinician rather than self-treat.
Menopausal mood symptoms
Some studies in perimenopausal and menopausal women have looked at SJW for mood, irritability, and quality of life, and a few have paired it with black cohosh. This is a separate, more limited area of research than the core depression evidence and is not established by the references cited here.
Mechanism of action
Multi-neurotransmitter reuptake inhibition
Hyperforin inhibits neuronal reuptake of serotonin, dopamine, norepinephrine, GABA, and glutamate simultaneously by activating sodium conductive transient receptor potential channel 6 (TRPC6) — a unique mechanism entirely different from SSRIs or SNRIs. This broad neurotransmitter modulation explains both the antidepressant efficacy and the mild anxiolytic effects.
HPA axis and cortisol normalization
SJW normalizes HPA axis hyperactivity in depression by reducing CRH and ACTH-stimulated cortisol hypersecretion — addressing a key biological abnormality in major depression. Hypericin specifically appears to modulate glucocorticoid receptor sensitivity, restoring normal cortisol feedback regulation.
CYP3A4 and P-glycoprotein induction
Hyperforin strongly induces CYP3A4, CYP2C9, and intestinal P-glycoprotein expression via pregnane X receptor (PXR) activation — dramatically increasing the metabolism and elimination of numerous medications. This mechanism underlies the most clinically significant herb-drug interactions in herbal medicine.
Clinical trials
Comprehensive meta-analysis of 29 RCTs (5,489 patients) comparing SJW to placebo and standard antidepressants for mild-to-moderate depression.
5,489 patients with mild to moderate depression across 29 RCTs.
SJW significantly more effective than placebo (RR 1.48). Comparable efficacy to standard antidepressants (RR 1.01). Significantly fewer patients dropped out due to adverse effects vs. antidepressants (0.8% vs. 3.0%). Established SJW as evidence-based treatment for mild-to-moderate depression.
Randomized, double-blind trial of SJW extract vs. light therapy vs. combination in 301 patients with seasonal affective disorder.
301 SAD patients. Winter season intervention.
SJW monotherapy equally effective to bright light therapy for SAD. Combination of SJW + light therapy showed trend toward greater improvement. Both treatments well-tolerated. Establishes SJW as effective SAD treatment.